Inaugural Request for Proposals (RFP) for Translational Clinical Research funding
The GMJ Foundation is pleased to announce the inaugural Request for Proposals (RFP) for Translational Clinical Research funding.
Over the past two years, GMJ Foundations has been involved in a Capital Campaign and has enlisted donors willing to invest in innovative projects that bridge the gap between scientific discovery and meaningful clinical impact. For the inaugural funding cycle, we anticipate awarding approximately $100,000 in total funding, with the possibility of support for 1-2 projects towards proposals that specifically bridge that gap. Final award amounts and the number of projects funded will depend on the applications received and available funding.
Priority will be given to proposals who are able to demonstrate that funding will result in meaningful clinical impact for patients. Examples of the type of Translational Clinical Research projects we are looking to support are identified in the attachment entitled Translational Clinical Research Information and Policies.
Below you will find links to the necessary documents for application:
• Application Guidelines for Translational Clinical Research
• Translational Clinical Research Information and Policies
• Evaluation Criteria for Translational Clinical Research
• Timeline for Translational Clinical Research proposal submission and review
For clarity, the GMJF will continue to offer an opportunity in January 2027 for proposals for MD research as we have been doing for decades. This inaugural RFP for Translational Clinical research opportunity is a separate and new funding opportunity due to the generous donations of donors during our Capital Campaign.
Applications for consideration will be due by noon on Friday September 18,2026. Please email Sue Self at sueselfhome@comcast.net with any questions. On behalf of the GMJF, we look forward to receiving your proposals and to supporting those proposals that will demonstrate the ability to bridge the gap between scientific work and meaningful clinical impact.
